25P-NBOMe (2C-P-NBOMe, NBOMe-2C-P) is a derivative of the phenethylamine 2C-P. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5-HT<sub>2A</sub> receptor. 25P-NBOMe has been sold as a drug and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe.
The dose range of 25P-NBOMe has been given as 0.1 to 1.5mg sublingually, with a typical dose estimate of 0.6mg.
25P-NBOMe is a potent agonist of the serotonin 5-HT<sub>2</sub> receptors, including the serotonin 5-HT<sub>2A</sub> receptor.
25P-NBOMe was first described in the scientific literature by 2012.
25P-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.